Full Press Release Details
DUBLIN , Feb. 29, 2024 /PRNewswire/ -- Medtronic (NYSE: MDT ), the global leader in healthcare technology, today announced it filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware , to block Axonics from improperly importing and selling products that infringe two Medtronic patents related to the MRI compatibility of implantable medical devices.
"Medtronic is continuing our efforts to stop Axonics from profiting off of their unauthorized use of our innovations and intellectual property," said Mira Sahney , president of the pelvic health business in the neuroscience portfolio at Medtronic. "The pattern is clear: Axonics uses Medtronic technologies to improperly compete in the market. It is time for Axonics to be held accountable for these unlawful acts."
Medtronic is asking the ITC to investigate and exclude the importation of the infringing Axonics products into the United States .
Medtronic currently has a separate infringement suit pending in the U.S. District Court for the Central District of California in which it asserts that Axonics has infringed additional technologies developed by and belonging to Medtronic.
About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT ), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
| Contacts: | |
| Laurel Hood | Ryan Weispfenning |
| Public Relations | Investor Relations |
| +1-763-514-0249 | +1-763-505-4626 |
SOURCE Medtronic plc